Peer-reviewedCC BY-NCCancer medicine
Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
- 1The First Affiliated Hospital of Chongqing Medical University
Related
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
- Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
- Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax.
- Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
BibTeX
@article{ren2026infection,
title = {{Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study}},
author = {Guilin Ren and Guangyu Zhou and Hao Zhou and Xi Dou and Lin Liu and Jianbin Chen and Xiaoqiong Tang and Hongbin Zhang and Xin Wang and Xiaohua Luo and Li Wang},
journal = {Cancer medicine},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13658937},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
AU - Guilin Ren
AU - Guangyu Zhou
AU - Hao Zhou
AU - Xi Dou
AU - Lin Liu
AU - Jianbin Chen
AU - Xiaoqiong Tang
AU - Hongbin Zhang
AU - Xin Wang
AU - Xiaohua Luo
AU - Li Wang
PY - 2026
DA - 2026/10/01
JO - Cancer medicine
UR - https://europepmc.org/article/PMC/PMC13658937
SN - 2045-7634
ER -